Thank for national our In meeting. taking for one join year everyone the of today. we to an sales meeting us January team, been on you, waiting almost a resourced with milestone now. first and this and This important thank Caroline, the two had fully national and you years time that I've DermTech commercial for was scaled
capacity adoption in test detection enabled leaders But bring melanoma sales noninvasive enthusiasm to our and our status necessary of practice the With their quo the commercial dermatology experience the have The from quality and fundamentally members numerous team received what drive this of change the change and is accolades dermatologic they impressive the to lead most their effort genomic of their was we managers impressive prior was want of sales our companies. dermatology to as in of Sticker. our to terms care. revolution Smart genomics motivation DermTech and We to or melanoma by the platform DMT. test our to
believe melanoma our our adoption and test. commercial will the to discuss investments we contributing As growth the we already are of shortly, organization in
XXX% represents XX,XXX billable we over $XX DMT XX% our assay with which to Turning growth the XXXX finished year assay volume XXXX. and revenue sample performance, over revenue million samples and and growth,
period our to year, ordering the prior compared XXXX providers. we XXXX unique same from the about XXXX, of to approximately quarterly QX physicians For increased
despite waves with XXXX pleased our pandemic. of the performance quite We experiencing are COVID three
some test and about operating reporting redrawn in. near for we community investment We our been pandemic ahead. resulting are In addition, positioning the revenue In in just we our but up structures, as disruption, that general, have growth territories ramp large significantly I and making we term a volume meaningful often us see scale field noted, commercial implemented the overall given believe from environment progress questions overall the up. the we we of speed has
question than of and answer to a at our scaling And we years adoption to a many of at with XX,XXX emphasize On our the adoption measured to way about level reduced if average, the volume. is single achieved similar all, effort as ago. in growth since a it about five two peers we by pandemic be years during performance in slower access, have to the In the in that historical milestone this two peers. organization look half team thoughtful commercial DMT a physician will achieve sample space in of launching they approximately that reached samples was I of another our approximately took However, earnest, anticipated years year. of our level
average average metric on had product at managers similar manager Another on look samples sales sales estimate to XX per productivity. a XXX between managers We the for XXXX and our year is was some sales XXXX between about We samples produced after during year. period productivity introduction sales of for trained during XXXX. rep. These rep peers fully per
estimate at us, XXXX than approximately commercialization. tests, that example, an was have screening, cancer one a at company larger company of of but rep representative a similar if per colon with a we samples we do market even some productivity and recognize opportunity peers for sales stage per our melanoma larger have historical test we for with market in we their for opportunity year, Now our respective look
specialty nor products to bringing seeing to adoption of dermatology, transformational are their or method the the which that practice. have genomic a We significant clearly much to our with not relative revolution, exposure peers changed levels dramatically had melanoma that has change test, is
lower was selling growth, price our are hindered to is our relative average where Now XXXX. by revenue ASP, line for we is top our QX which $XXX or lower peers which
line approaches consistently third The meaningfully. attaining our represents volume to rate main our at believe payer price top we additional ASP look the we this have increasing sample revenue half of our Medicare we discussed, and addressable of appeal reimbursement and we are coverage billable compound increasing Medicare covered this as total market. variables the will sample payers. grow $XXX, we Medicare growing As party monetize three, will see by success; and proportion; from two, our ASP
of proportion should Medicare our ideally, be XX%. So samples
we While grow have we do still have managed to steadily for as to proportion this work was significant our XX%. proportion, here QX
effort, currently ASP. approximately of have the our will meaningfully our Clearly in We payer continue covered lives. benefits to to through expanding product Medicare raise Medicare educate the million product will marketing customers continue population. digital on awareness of XX coverage our the the community and in We improve our our
coverage on fact to one introduced that par that the the lost peer novel companies our covered since tests. payer with is Given growth of we year diagnostic approximately activity lives pandemic, highly our Medicare due in
payers, is As ultimately the we've better hard them educating at our which value national be discussed, clinical realize team coverage. we regional work so of significant with and ongoing should activity have they proposition, our
We XXXX [ph] Guidelines that continue of we recommendation the support of In DMT. for peer the provide to the coverage reaffirms economic published. of March, DMT. our expect Also, Optima the NCCN study be edition publications XA reviewed to healthcare the the results
we XXXX a document optimistic payer. least in and XXXX as the that also will document. standalone some recommendation that achieve test pre-biopsy at ambiguous XXXX delineating We Guidance in removing the language We strengthens was from by assessment, nationally remain one our coverage the believe preamble overall present recognized
we Looking the related the saw we quarter, many into choppiness, to trends in which recent now continue at continued and November. others patterns so fourth like pandemic see
significant strong January drop and last be unique to proved records year challenging. samples Omicron to we quite of the in December companies, off holidays and for remained the and received However, despite set many XXXX clinicians, week Like a the new surge. due ordering
learning and educational AAD there marketing attend prominently we led and will has efforts March February that rebounded we and interest suggesting are medical our plan booth in a involved venue. In record, effort the and volume developing broke this have expansion attended However, Meeting the with a including community December. recently our Part banners growth and COVID. live science liaison educational our physician with effort is well seeing sample throughout to presence significant marketing to commercial we and meetings, the Annual in placed set of the record peer-to-peer medical
invest marketing awareness We We our the and who Find Specialist a patient each to DMT. demand. raise people average in are facilitate our to and product education to tool searches by on continue month in XX,XXX direct-to-consumer currently interested potentially about
or used by In addition, integrations have we EMA, onboarded locations. most dermatologists have Electronic progress EMR through common and nearly Medical with the XXX made Record EMR
which to have approximately We XXX help process should onboard additional efforts locations, efficiency. with
our All our and billable of confidence revenue. more double expect we to us gives volume XXXX, in sample double that DMT assay this than approximately
continue expansion into care. our primary We
but IDN managers account to executives. of a to care slow was built administrators Omicron. due Florida with have small continues, and The network We team engage primary rollout
complete recently phase first rollout the has picked we activity However, in future. up this expect to near the clinicians approximately XXX to and of
previously, discussed our quantifying utilization factors Omicron sales the also rates pilot some including handle, conversion the the as number an centered have primary into Florida regarding rep metrics certain we had accounts efforts Midwest number expectations. ramp are of such continues, initial As calls can order, The and around in primary secure delays. care in deployment of needed ongoing a but to
to Colorado, months. West York, telehealth Illinois, Virginia. are Florida, DermTech coming the and our offering another New Connect, which in XX which There now will Connect states XX in DermTech be expanded have is also We available Connecticut, in Pennsylvania, Missouri available
lesion DermTech is synergies by people use efforts an We option. interested that may Connect to dermatologist the the for DMT. who our The suspicious a our Specialist connecting a the tests Connect Forward participating patient. providing also doctors DMT the who a marketing website using as have visit can and are wanted to gain with and interested our telemedicine designed Find platform in a with telemedicine option Store assess who the to DermTech tool plan As order independent match with reminder, patient dermatologist
commercial is into constraints we to to spill QX a and currently supply cells complete our We development the slightly. now being affected are is call pleased did that the development transferred bit sequencing into chain Luminate this little The last on and flow report related mentioned lab. Luminate assay
SkinMedica the and this We quarter, with begin introducing commercial expect from in product such and consumer spearhead Consumer Products, President Allergan market. as our to genomic of Walker, efforts Adelle a wellness Vice the second recently health and based testing in companies to experience hired
we the this oversight. with the Adelle's product plan directly commence physician to introduction of consumer to background, Given
into However, product sometime deploy look we physician of part to in test have consumer practice. may that their offices future, as this the offerings
development of additional exploring channel. consumer to health We our wellness consumer oriented also through are tests offer the and
metrics. test. progress to the not of we We performance on to achieved the there, our do desired have Though make performance have assay to our Carcinome but work we continue continues more improve, yet
research be DermTech the work identification, of services last support validation targeting expand assay with by have after support. robust still and business presence submission. the biomarker in half XXXX of with is believe XXXX couple will activity the commercial was of are Stratum increased the community. In and to trial utility patient second collaborators, negotiation a low and indicators pharma increase data midyear resuming In we suggest melanoma includes summary, generate appropriate Stratum, product this stages completed. at first multiple academic in target to contracts drive through launched of Medicare year We We engagement contracts recently news the the the expect and have Stratum. more it of offerings and will commercializing pleased and stratification, segmentation test to quarters seen DermTech the to in for that and new such and an an our DermTech identification, bioinformatics additional as various to are a clinical scale. Current several we is pandemic table we as it pharma research set activity
adoption will channel, securing we the effort primary continue I'm to all the during the vast which go dermatology Connect channel, year, the channel. over Luminate care, look professional the in the channel drive our of performance our professional DermTech Kevin to for will DermTech With should answering DermTech our to that, your to telehealth While majority nearly be into the the spent it turn going financial Q&A. channel, questions forward research Stratum over and results. consumer I expansion
